DaVita Inc. found using ticker (DVA) have now 7 analysts covering the stock. The analyst consensus points to a rating of ‘Hold’. The target price ranges between 109 and 74 with the average target price sitting at 90.86. Now with the previous closing price of 82.01 this is indicating there is a potential upside of 10.8%. The day 50 moving average is 80.34 while the 200 day moving average is 83.53. The market cap for the company is $7,250m. Find out more information at: https://www.davita.com
The potential market cap would be $8,032m based on the market concensus.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
